BAD: A good therapeutic target?

Breast Cancer Research

Volumn 5, Issue 1, 2003, Pages 27-30

  Motoyama, Andrea B ^a   Hynes, Nancy E ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Apoptosis; ErbB1 receptor; Insulin growth factor 1; Mitogen activated protein kinase; ZD1839

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL SURVIVAL; DRUG MECHANISM; DRUG TARGETING; ERADICATION THERAPY; HUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN TARGETING; STRESS; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BREAST NEOPLASMS; CARRIER PROTEINS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0038404976     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr552     Document Type: Article

References (24)

1. Gilmore A, Valentijn A, Wang P, Ranger A, Bundred N, O'Hare M, Wakeling A, Korsmeyer S, Streuli C: Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002, 277:27643-27650.
2. Olayioye M, Neve R, Lane H, Hynes N: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
3. Shawver L, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
4. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-6565.
5. Van Obberghen E, Baron V, Delahaye L, Emanuelli B, Filippa N, Giorgetti-Peraldi S, Lebrun P, Mothe-Satney I, Peraldi P, Rocchi S, Sawka-Verhelle D, Tartare-Deckert S, Giudicelli J: Surfing the insulin signaling web. Eur J Clin Invest 2001, 31:966-977.
6. Zhang X, Yee D: Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000, 2:170-175.
7. Igney F, Krammer P: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2:277-288.
8. Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
9. Bonni A, Brunet A, West A, Datta S, Takasu M, Greenberg M: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999, 286:1358-1362.
10. Shimamura A, Ballif B, Richards S, Blenis J: Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol 2000, 10:127-135.
11. Zhou X, Liu Y, Payne G, Lutz R, Chittenclen T: Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 2000, 275:25046-25051.
12. Datta S, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg M: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
13. Harada H, Andersen J, Mann M, Terada N, Korsmeyer S: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001, 98:9666-9670.
14. Dramsi S, Scheid M, Maiti A, Hojabrpour P, Chen X, Schubert K, Goodlett D, Aebersold R, Duronio V: Identification of a novel phosphorylation site, Ser-170, as a regulator of bad pro-apoptotic activity. J Biol Chem 2002, 277:6399-6405.
15. Zha J, Harada H, Yang E, Jockel J, Korsmeyer S: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996, 87: 619-628.
16. Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata J, Wang H, Shabaik A, Tudor G, Krajewski S, Myers T, Johnson G, Sausville E, Reed J: Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol 1998, 152:51-61.
17. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
18. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J: Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001, 21: 499-512.
19. Lynch D, Yang X: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol 2002, 29:47-50.
20. Brandt R, Wong A, Hynes N: Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene 2001, 20:5459-5465.
21. Bruns C, Solorzano C, Harbison M, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler I: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000, 60:2926-2935.
22. Holinger E, Chittenden T, Lutz R: Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 1999, 274: 13298-13304.
23. Cosulich S, Worrall V, Hedge P, Green S, Clarke P: Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol 1997, 7:913-920.
24. Konishi Y, Lehtinen M, Donovan N, Bonni A: Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell 2002, 9:1005-1016.